News Archive

2017

June

Media Release / Jun 20, 2017

Novartis RTH258 (brolucizumab) demonstrates robust visual gains in nAMD patients with a majority on a 12-week injection interval

Read More
Media Release / Jun 20, 2017

Novartis real world study shows almost half of chronic urticaria patients are not receiving any treatment despite significant disease burden

Read More
Media Release / Jun 19, 2017

Sandoz receives approval in Europe for Rixathon® (biosimilar rituximab) to treat blood cancers and immunological diseases

Read More
Media Release / Jun 17, 2017

Novartis International AG: New patient survey highlights need for more action to help severe asthma patients gain control of their disease

Read More
Media Release / Jun 15, 2017

FDA accepts Sandoz regulatory submission for a generic version of Advair Diskus®

Read More
Media Release / Jun 15, 2017

Novartis' Cosentyx shows sustained improvements in signs and symptoms for both AS and PsA in up to 80% of patients at 3 years

Read More
Media Release / Jun 08, 2017

Novartis presents data demonstrating efficacy of AMG 334 (erenumab) in migraine prevention at the American Headache Society Annual Meeting

Read More
Media Release / Jun 07, 2017

Novartis interim results from global, pivotal CTL019 trial show durable complete responses in adults with r/r DLBCL

Read More
Media Release / Jun 06, 2017

Novartis drug Tasigna receives EU approval for inclusion of Treatment-free Remission (TFR) data in product label

Read More
Media Release / Jun 05, 2017

Novartis announces clinical collaboration with Bristol-Myers Squibb to evaluate potential treatments in metastatic colorectal cancer

Read More

Pages

Related Links

Annual Report 2016

Review the strategy and annual performance of Novartis and read letters from our Chairman and CEO.

Learn More

Contact Media Relations

For media and journalist inquiries, please contact the Novartis Corporate Media Relations office by email or telephone.

Central Media Line:
Phone: +41 61 324 2200